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Abstract
Background/Aims: Dietary potassium (K+) has beneficial ef-
fects on blood pressure and cardiovascular (CV) outcomes. 
Recently, several epidemiological studies have revealed an 
association between urinary K+ excretion (as proxy for di-
etary intake) and better renal outcomes in subjects with 
chronic kidney disease (CKD). To address causality, we de-
signed the “K+ in CKD” study. Methods: The K+ in CKD study 
is a multicenter, randomized, double blind, placebo-con-
trolled clinical trial aiming to include 399 patients with hy-
pertension, CKD stage 3b or 4 (estimated glomerular filtra-
tion rate [eGFR] 15–44 mL/min/1.73 m2), and an average 
eGFR decline > 2 mL/min/1.73 m2/year. As safety measure, all 
included subjects will start with a 2-week open-label phase 
of 40 mmol potassium chloride daily. Patients who do not 
subsequently develop hyperkalemia (defined as serum K+ 
>5.5 mmol/L) will be randomized to receive potassium chlo-
ride, potassium citrate (both K+ 40 mmol/day), or placebo for 
2 years. The primary end point is the difference in eGFR after 
2 years of treatment. Secondary end points include other re-
nal outcomes (> 30% decrease in eGFR, doubling of serum 
creatinine, end-stage renal disease, albuminuria), ambula-
tory blood pressure, CV events, all-cause mortality, and inci-
dence of hyperkalemia. Several measurements will be per-
formed to analyze the effects of potassium supplementa-
tion, including body composition monitoring, pulse wave 
velocity, plasma renin and aldosterone concentrations, uri-
nary ammonium, and intracellular K+ concentrations. Con-
clusion: The K+ in CKD study will demonstrate if K+ sup-
plementation has a renoprotective effect in progressive 
CKD, and whether alkali therapy has additional beneficial ef-
fects. © 2018 The Author(s)
Published by S. Karger AG, Basel
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Introduction
From prehistoric times to the current age, our diet has 
changed from a high potassium-low sodium diet to a low 
potassium-high sodium diet [1]. So far public health ef-
forts have largely focused on the high sodium component 
of our diet and on possible interventions to reduce it. Less 
emphasis has been placed on low K+ intake, while there 
are good reasons to do so. For example, the beneficial ef-
fects of dietary K+ on blood pressure and cardiovascular 
(CV) outcomes are increasingly recognized experimen-
tally and epidemiologically [2–7]. The recommendations 
by the World Health Organization, European Food Safe-
ty Authority, and U.S. Department of Health and Human 
Services to define dietary reference values for dietary K+ 
intake (90–120 mmol/day) are echoing this awareness [8–
10]. Of interest, recent studies also suggest an effect of 
dietary K+ on renal outcomes in patients with chronic 
kidney disease (CKD) [11–15]. That is, urinary K+ excre-
tion (as proxy for intake) was associated with slower pro-
gression of CKD in the majority of these studies (Table 1) 
[16]. Preliminary work in our own cohort confirmed this 
association in CKD patients [17].
Besides renoprotective effects, higher K+ intake has 
also been associated with a lower risk of CV events [2, 11, 
18]. For example, the PURE-study (including > 100,000 
subjects worldwide) showed inverse relationships be-
tween urinary K+ excretion, blood pressure, and CV out-
comes [6, 7]. A medium-sized clinical trial demonstrated 
that the use of K+-enriched salt reduced CV mortality in 
elderly men [19]. The beneficial effects of dietary K+ ob-
served in these epidemiological studies are supported by 
various physiological mechanisms. For example, dietary 
K+ induces natriuresis by dephosphorylating the sodium 
chloride cotransporter, providing a novel mechanism for 
its anti-hypertensive effect [20, 21]. In animals, dietary K+ 
also has protective effects in the vasculature and the kid-
ney through inhibition of transforming growth factor β 
and suppression of reactive oxygen species [22–25]. 
Our preliminary data also clearly indicate that patients 
with CKD generally have a low urinary K+ excretion 
(92.7% < 90 mmol/day, Fig.  1). Collectively, these data 
now pave the way for an intervention study to address 
causality and identify involved pathways [16, 26–28]. 
This should answer the question whether correcting the 
dietary K+ deficit in patients with CKD may contribute to 
better renal and CV outcomes. Therefore, we hypothesize 
that K+ supplementation in patients with CKD will slow 
the progression of CKD (Fig. 3). To address this hypoth-
esis, we have designed a randomized clinical trial in pa-
tients with CKD stages 3b or 4 (estimated glomerular fil-
tration rate [eGFR] range 15–44 mL/min/1.73 m2). Inter-
estingly, in our preliminary data, K+ excretion only 
showed a weak association with serum K+ (Fig. 2), sug-
gesting that K+ intake is not the primary determinant of 
serum K+, and that K+ supplementation in patients with 
CKD may be safe. However, hyperkalemia remains a 
dreaded complication in CKD and we acknowledge this 
safety concern [29]. Therefore, patients will start with a 
run-in phase of 2 weeks with potassium chloride to eval-
uate if hyperkalemia ensues. For patients included in the 
trial, a strict monitoring protocol analogous to the recent 
hyperkalemia trials testing the novel K+ binders, will be 
adopted [30, 31]. 
Our research question will be linked to the recent evi-
dence that alkali therapy also slows the progression of 
CKD [32, 33]. To this end, the clinical trial will include 3 
arms, namely, placebo, potassium chloride, and potassi-
um citrate. The trial is powered for a relevant primary end 
point, namely, 2-year eGFR-decline (estimated by CKD-
EPI), and is planned to include 399 patients. Secondary 
end points will include ambulatory blood pressure, albu-
minuria, and CV parameters. In addition to 4 university 
medical centers, 16 affiliated hospitals will collaborate in 
patient recruitment. Together, we believe this interven-
tion study will address a highly relevant question in the 
field of CKD progression and outcomes. 
Materials and Methods
Study Setting and Population
The “K+ in CKD” study is designed as a multicenter, double-
blind, randomized, placebo-controlled 3-arm trial in 399 partici-
pants with progressive CKD and hypertension. It will include adult 
patients (≥18 years) with hypertension (office blood pressure > 
140/90 mm Hg or use of anti-hypertensive drugs), and CKD stage 
3b or 4 (eGFR of 15–44 mL/min/1.73 m2) with evidence of pro-
gression in the preceding years (> 2 mL/min/1.73 m2 in the preced-
ing ≥1 year with at least 3 measurements). Detailed patient inclu-
sion and exclusion criteria are listed in Box 1. Patients will be re-
cruited from the nephrology outpatient clinics of the 4 
participating university medical centers (Amsterdam, Groningen, 
Leiden, and Rotterdam) and 16 affiliated hospitals (online suppl. 
Fig. S1; for all online suppl. material, see www.karger.com/
doi/10.1159/000490261). 
Study Design
Individuals meeting the entry criteria will be enrolled in one of 
the 4 university medical centers. The planned recruitment period is 
24 months. After informed consent is obtained and eligibility is as-
sessed (Box 1), patients will start with the open-label run-in phase 
followed by the randomization phase. Figure 4 shows a schematic of 
the trial design .There will be 7 study visits (V0–V6) in which visits 
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Fig. 1. Urinary K+ excretion in patients with CKD. Preliminary 
work in our outpatient department showing the distribution of 
24-h urinary K+ excretion (as proxy for intake) in patients with 
CKD stages 3b and 4 (estimated glomerular filtration rate of 15–44 
mL/min/1.73 m2), indicating that the majority of patients (92.7%) 
consumes less K+ than recommended (90 mmol/day). CKD, 
chronic kidney disease; K+, potassium.
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Fig. 2. Correlation between urinary K+ excretion and serum K+ 
concentration. Preliminary data illustrating that in patients with 
CKD 3b and 4 (eGFR of 15–44 mL/min/1.73 m2) urinary K+ excre-
tion (as proxy for intake) is only weakly correlated with the serum 
K+ concentration. CKD, chronic kidney disease; CrCl, creatinine 
clearance; eGFR, estimated glomerular filtration rate. 
Table 1. Summary of cohort studies analyzing the association between urinary potassium excretion and renal outcomes
First author (cohort) n Primary
endpoint
eGFR,
mL/min/
1.73 m2
Median
follow-up
Cut-offs for
urinary K+,
g/day
Main conclusion
Smyth [13]
(ONTARGET and 
TRANSCEND)
28,879 30% eGFR
decline, RRT
68±18 4.7 years 1.7 and 2.7 Primary endpoint 
lower in tertile 2
and 3
Araki [11] (Shiga) 623 RRT, CV events 88±17 11 years 1.7 (ref.), 2.3, 2.9 Primary endpoint 
lower in quartile 3
and 4
He [12] (CRIC) 3,939 50% eGFR decline,
incident ESRD
44±15 Not mentioned 1.5 (ref.), 2.0, 2.6 Primary endpoint 
higher in quartile 4
Kieneker [14]
(PREVEND)
5,315 eGFR <60 or
albuminuria
>30 mg/day
97±6 10.3 years Continuous
analysis
Each 1-SD urinary K+ 
↓ 16% higher risk of 
primary endpoint
van Noordenne [17]
(Amsterdam)
901 Composite
all-cause mortality,
CV and renal events
97±36 12.7 years 2.3 and 3.1 Primary endpoint 
lower in tertile 3
Leonberg-Yoo [15] 
(MDRD)
812 RRT, all-cause
mortality
32±12 6.1 years Continuous
analysis
Each 1-SD ↑ baseline 
urinary K+ adjusted 
HR of 0.83 for
mortality
CV, cardiovascular; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; K+, potassium; ref., 
reference; MDRD, modification of diet in renal disease; RRT, renal replacement therapy. Conversion factor for units: K+ in g/day to 
mmol/day, ×25.6.
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V0 (–2 weeks) and V1 (baseline) represent the start and end of the 
open-label phase, and visits V1–V6 the start and end of the random-
ized phase. The use of an angiotensin converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB) is allowed. In con-
trast to previous trials, we do not require maximum tolerated ACEi 
or ARB because we wanted to interfere as little as possible in the 
clinical management of the patients (study visits are independent of 
regular nephrology care). In addition, maximum-tolerated ACEi or 
ARB may have increased the risk for hyperkalemia and may have 
introduced a hemodynamic eGFR-decrease that would complicate 
the interpretation of the potassium effect on eGFR. In case the pa-
tient is using drugs listed in the exclusion criteria (e.g., spironolac-
tone or dual renin angiotensin aldosterone system [RAAS]-block-
ade) but without a strict medical reason to continue this, this drug 
may be discontinued or switched, if the patient and the prescribing 
physician agree to do so. The actual stopping of the drug will take 
place after signing informed consent during the first study visit. This 
study visit will be labeled “Visit Stop Drug” (VSD) and will precede 
V0. This implies that, in this specific circumstance, patients will have 
1 additional study visit (VSD) and that the complete study period 
will be 2 weeks longer. The total duration of the study will be 104 
weeks (+2 weeks in case of VSD). A randomization list using block 
randomization has been prepared by an independent statistician 
from the Department of Biostatistics, Erasmus Medical Center (ran-
domization 1: 1: 1). The supplement manufacturer (see further) has 
printed the randomization numbers on the label of the containers 
with the study capsules. The randomization list with allocation is 
only known to the independent statistician, manufacturer, and the 
Pharmacy of the Erasmus Medical Center (which saves the list and 
is reachable 24h/day for emergency unblinding). 
CKD progression
Hypertension
High Na+ - low K+ diet K+ supplementation
Vascular effects
Renoprotective effect
(anti-inflammatory, anti-fibrotic, anti-oxidant)
Na+ balance
Worse CV outcomes
Current situation Proposed effects of intervension
Fig. 3. Proposed pathways for the beneficial 
effects of K+ supplementation in CKD. CV, 
cardiovascular; CKD, chronic kidney dis-
ease; K+, potassium; Na+, sodium.
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Box 1. Inclusion and exclusion criteria
Inclusion criteria 
– Adults (≥18 years)
– CKD stage 3b or 4 (eGFR range 15–44 mL/min/1.73 m2)
– Δ eGFR >2 mL/min/1.73 m2/year
– Hypertension
Exclusion criteria
– Hyperkalemia (serum K+ >5.5 mmol/l) at study visit V0
–  Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers, potassium-sparing diuretics, or oral K+ 
binders
– Patients using calcineurin inhibitors
– Kidney transplant recipients
– Patients with an active gastro-intestinal ulcus
– Patients with previous history of ventricular cardiac arrhythmia
– Patients with a life expectancy <6 months
– Expected initiation of renal replacement therapy <2 years
–  Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the  research team
– Women who are pregnant, breastfeeding or consider pregnancy in the coming 2 years
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; K+, potassium; RAAS, renin angiotensin aldosterone 
system.
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Trial Treatments
Investigational products (potassium chloride and potassium 
citrate) are classified as food supplement and listed as such on the 
European list of accepted food supplements. The active treatments 
provide 40 mmol (1,564 mg) K+/day and either 40 mmol (1,418 
mg) Cl–/day or 13.3 mmol (2,555 mg) citrate/day. This dose was 
selected because it represents the amount of K+ necessary to in-
crease the average dietary K+ intake in patients with CKD (50 
mmol/day) to the recommended minimum intake (90 mmol/day, 
Fig. 1). We acknowledge that true dietary K+ intake may have been 
higher than 50 mmol/day because of fecal K+ excretion, which is 
increased in CKD [26, 34, 35]. However, even if this is true, dietary 
K+ intake with supplementation is unlikely to exceed 120 mmol/
day, therefore falling within the recommended reference range [8–
10]. The study will use placebo as a comparator. The placebo con-
sists mainly of starch. The capsules with potassium chloride, potas-
sium citrate, and placebo will be produced specifically for this clin-
ical trial by a large and accredited food supplement laboratory (Lab 
Medisan, Heerenveen, The Netherlands, www.lab-medisan.com) 
with previous experience in this type of supplementation studies 
[36]. All patients will receive an information card with direct con-
tact information to the research team and instructions to contact 
the research team in the following 3 situations. The first situation 
is when they start any novel drug (prescription or over-the-coun-
ter) or find a need to use non-steroidal anti-inflammatory drugs. 
The reason to do so is that several commonly used drugs (e.g., co-
trimoxazole, non-steroidal anti-inflammatory drugs) predispose 
to hyperkalemia, especially in patients using RAAS-blockers [37, 
38]. The second situation is in the case of dose adjustments of pre-
scribed drugs (e.g., RAAS-blockers), when the research team will 
decide whether this justifies earlier monitoring of serum K+ 
through an additional study visit. The third situation is in case of 
vomiting, diarrhea, or hospital admission, when we will temporar-
ily discontinue the study supplements to prevent hyperkalemia.
Standard Care
Patients will maintain their regular diet and prescribed medica-
tions. Some of the patients with CKD will have been referred to a 
dietitian who may have started a low sodium and/or low K+ diet. If 
so, patients may continue this as part of their standard care. We will 
record which patients have received such dietary recommenda-
tions. Patients will continue to be monitored by their own nephrol-
ogist. If possible, such visits may be combined with study visits. 
Primary and Secondary End Points
The primary and secondary end points of the trial are shown in 
Box 2. The primary end point is the difference in eGFR (using the 
CKD-EPI creatinine equation) as measured at the end of the study 
(V6) and at baseline (V1). The secondary endpoints include a 
number of established renal and CV outcomes (Box 2). The eGFR 
slope was considered the primary end point but requires the as-
sumptions that eGFR decline is constant and that the treatment 
effect does not depend on the rate of eGFR decline. We could not 
exclude the possibility that 1 or both of these assumptions would 
be violated.
Data Collection and Measurements
The measurements during the study visits are summarized in 
Table 2 and online supplementary Table S1. In addition to gen-
eral CKD parameters, we will also measure intracellular K+ in 
erythrocytes. Although one might expect a higher total body K+ 
in CKD, previous studies in CKD and dialysis patients showed K+ 
deficiency [34, 39]. In case of hyperkalemia, an algorithm will 
be followed with explicit criteria when to perform an ECG, inten-
sify monitoring, or discontinue supplements (online suppl. Fig. 
S2). A Clinical Data Management System will be used that meets 
the ICH-GCP and FDA 21 CFR part 11 criteria (Research Man-
ager®, www.deresearchmanager.nl). Personal data will be han-
dled in compliance with the Dutch Personal Data Protection Act. 
Data will be handled confidentially using a unique code. A subject 
identification code list will be used to link the data to the subject. 
The research team has access to the source data. 
Estimation of Power and Sample Size
A power calculation was performed in collaboration with a stat-
istician (Dr. M.A.J. de Ridder, Erasmus Medical Center). The study 
has 3 arms (placebo, potassium chloride, potassium citrate), and 
therefore 2 separate analyses for the primary end point will be per-
Inclusion
CKD3b or 4
Δ eGFR >2 mL/min/year
Hypertension
Exclusion
Ventricular arrhythmia in
medical history
Dual RAAS-blockade
MR-blocker
40 mmol/K+-chloride/day
No inclusion if
hyperkalemia develops
K+-chloride (n = 133)
K+- citrate (n = 133)
Placebo (n = 133)
Screen Run-in Randomization Treatment period Endpoints
V0
V2 V3 V4 V5
Primary
Δ eGFR
Secondary
Blood pressure (ABPM)
Albuminuria
CV events and mortality
V6
V1
Fig. 4. Clinical trial design with main inclusion and exclusion cri-
teria and primary and main secondary outcomes. ABPM, ambula-
tory blood pressure measurement; CKD, chronic kidney disease; 
CV, cardiovascular; eGFR, estimated glomerular filtration rate; 
K+-Chloride, potassium chloride; K+-Citrate, potassium citrate; 
MR, mineralocorticoid receptor; RAAS, renin angiotensin aldo-
sterone system. V0, t = –2 weeks; V1, t = 0; V2, t = 1 month; V3, 
t = 6 months; V4, t = 12 months; V5, t = 18 months; V6, t = 24 
months.
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Table 2. Measurements
Measurement Category Specification
Blood General CKD parameters Creatinine, K+, bicarbonate, urea, sodium,
calcium, phosphate, albumin, hemoglobin
CKD-MBD Parathyroid hormone, alkaline phosphatase,
FGF23
Volume parameters Renin, aldosterone, NT-pro-BNP
Intracellular K+ Erythrocyte K+ concentrations
Genetics DNA-isolation for SNP-analysis
Urine (24-h and spot) Kidney function and
nutrition status
Creatinine, urea, albuminuria
Electrolytes Sodium, K+, calcium
Acid-base Ammonia, citrate
Cardiovascular and
volume parameters
BP ABPM, office BP
Vascular stiffness Pulse wave velocity
Body composition Bioimpedance measurements
ABPM, ambulatory BP measurement; BP, blood pressure; CKD, chronic kidney disease; CKD-MBD, chronic 
kidney disease – mineral and bone disorder; FGF 23, fibroblast growth factor 23; K+, potassium; NT-pro-BNP, 
N-terminal prohormone of the brain natriuretic peptide; SNP, single nucleotide polymorphism.
Box 2. Primary and secondary endpoints
Primary end point
Difference in eGFR after 2 years of treatment 
Secondary end points
Renal outcomes
– ≥30% decrease in eGFR
– eGFR slope analysis 
– Doubling in serum creatinine or ESRD
– Progression to next CKD or albuminuria class
– Albuminuria
Cardiovascular outcomes
– Ambulatory blood pressure
– Volume and cardiovascular markers (pulse wave velocity, bioimpedance measures, NT-pro-BNP)
– Cardiovascular events (cardiovascular death*, non-fatal myocardial infarction, non-fatal stroke, unstable
angina, resuscitated cardiac arrest)
Other outcomes
– All-cause mortality
– Incidence of hyperkalemia*
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; 
NT-pro-BNP, N-terminal prohormone of the brain natriuretic peptide.
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formed (placebo vs. potassium chloride and placebo vs. potassium 
citrate). To account for this multiple testing, α will be set at 0.025. 
To assess the variability in the primary endpoint (Δ eGFR in 2 years), 
we used a sample of real-life CKD patients from our own outpatient 
clinic that would be eligible for participation in this trial (n = 40). 
The standard deviation of Δ eGFR in this group of patients was 7.8 
mL/min/1.73 m2. The expected effect of the interventions was based 
on a previous study in which sodium bicarbonate was also given for 
2 years to reduce CKD progression. This study showed that this in-
tervention resulted in a reduction of CKD progression of 4.05 mL/
min/1.73 m2 eGFR in 2 years [40]. For our sample size calculation, 
we used a slightly more conservative expected effect of 3 mL/
min/1.73 m2 in 2 years. These variables were entered in a sample size 
calculator and indicated that 260 patients would be required. There-
fore, for our study with 3 arms, this would result in 390 patients. We 
decided to aim for a slightly higher number of randomized patients, 
namely, 399 patients. The flowchart with the anticipated patient 
numbers, including anticipated drop-out and withdrawal rates, is 
shown in online supplementary Figure S3. 
Statistical Analysis
The primary hypothesis test will be the difference between pla-
cebo and treatment groups after 2 years. The primary analysis will 
be an intention-to-treat analysis of the primary end point (Δ 
eGFR) in K+ supplementation (potassium chloride or potassium 
citrate) vs. placebo. 
The secondary analysis will be a per-protocol analysis of the 
primary endpoint (Δ eGFR) in either of the K+ supplementation 
arms vs. placebo. 
Ethical Considerations
The Medical Ethics Committee of the Erasmus Medical Center 
approved the protocol and informed consent form (METC-2017-
226). The study will be conducted according to the principles of 
the Declaration of Helsinki (version 2013) and in accordance with 
the Medical Research Involving Human Subjects Act. All partici-
pants have the right to withdraw at any time during the study. Fur-
ther, stopping rules for patients and the trial are provided in online 
supplementary Table S2.
The study is registered at www.ClinicalTrials.gov (study num-
ber: NCT03253172). 
Study Organization
A steering committee oversaw the design and will overview the 
conduct of the study. An independent data safety monitoring 
board has been established to monitor the safety of the trial and 
can advise to stop the study based on serious adverse events and/
or interim analysis of adverse effects (online suppl. Table S2). This 
data safety monitoring board will perform its analyses after inclu-
sion of 10% of the patients and half-yearly for the duration of the 
study. An independent monitor will evaluate the study progress 
and quality and completeness of study data 2 times per year.
Discussion
The K+ in CKD study seeks to determine whether K+ 
supplementation attenuates CKD progression. 
The association between dietary K+ intake, blood 
pressure, and outcomes has primarily been investigated 
in non-CKD populations. The relationship between K+ 
and blood pressure in the INTERSALT, PURE, and 
NHANES studies persisted after adjusting for con-
founding variables [6, 41, 42]. The DASH-trial was an 
intervention study and showed that with constant so-
dium intake, an increase in dietary K+ reduced blood 
pressure [43]. Subjects with hypertension were even 
more sensitive to the DASH-diet and responded with a 
threefold greater reduction in blood pressure. In a fol-
low-up study, the anti-hypertensive effect of dietary K+ 
was found to be greater when sodium intake was high-
er [44]. Although in the DASH-study the link between 
blood pressure and K+ could clearly be established by 
analysis of 24-h urines, other elements of the DASH-
diet may have contributed to the response. In this re-
gard, it is important to analyze studies in which the 
only intervention was K+ supplementation. A meta-
analysis, which included 22 randomized clinical trials, 
more conclusively dissected the effects of dietary inter-
ventions on blood pressure, pinpointing it to a direct 
effect of K+ [2]. The PURE study also explored the as-
sociation between urinary K+ excretion and CV out-
comes [7]. Compared to a urinary K+ excretion < 1.5 g/
day, higher urinary K+ excretion was associated with a 
lower risk of death or CV events. Although causality 
cannot be inferred from this epidemiological study, it 
is of interest to note that this association remained after 
correction for physical activity, dietary factors (includ-
ing caloric intake and sodium content), and blood 
pressure [7]. In addition to K+’s effect on blood pres-
sure, the meta-analysis also showed a 24% reduction of 
incident stroke [2]. The experimental literature corrob-
orates the notion that the CV protection of K+ primar-
ily concerns a reduced risk of stroke [18, 45]. Of inter-
est, this protective effect was independent of blood 
pressure and suggests a direct effect of K+ on endothe-
lial cells. For example, He et al. [3] performed a place-
bo-controlled cross-over trial comparing potassium 
chloride with potassium bicarbonate in 42 pre-hyper-
tensive individuals. Although the effects on blood pres-
sure were modest (possibly because these individuals 
consumed a relatively low sodium-high K+ diet), the 
effects on CV parameters were striking. Both potassi-
um chloride and potassium bicarbonate significantly 
improved endothelial function, increased arterial com-
pliance, decreased left ventricular mass, and improved 
left ventricular diastolic function. A Taiwanese study 
randomized a veteran retirement home to prepare 
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meals with K+-enriched salt or with sodium chloride in 
1,981 veterans [19]. Using this approach, the number 
of CV deaths nearly halved in the experimental group 
after a median follow-up of 2.5 years. 
Given the salt sensitivity of patients with CKD and 
their high CV burden, K+ supplementation may be espe-
cially effective in this multimorbid patient population. 
This hypothesis has recently been addressed in 6 
large CKD cohorts (Table 1) [11–16]. Smyth et al. [13] 
performed their analysis in the ONTARGET and 
 TRANSCEND cohorts. They found that higher 24-h uri-
nary K+ (but not sodium) was associated with a lower risk 
of renal outcomes (≥30% eGFR-decline or dialysis) [13]. 
Of interest, higher urinary K+ excretion was not associ-
ated with a higher incidence of hyperkalemia. This sug-
gests that dietary intake is not the primary determinant 
of serum K+ in CKD and adds to the safety of our pro-
posed K+ supplementation trial. Araki et al. [11] analyzed 
the association between 24-h urinary K+ excretion, renal 
outcomes, and CV events in Japanese patients with type 
2 diabetes. During a median follow-up of 11 years, 
 patients in the highest quartile of urinary K+ excretion 
(>2.9 g/day) had significantly fewer CV events, 50% re-
duction in eGFR, or start of renal replacement therapy 
than patients in the lowest quartile (< 1.72 g/day). Fur-
thermore, patients in the highest quartile showed less an-
nual eGFR-decline (–1.3 vs. –2.2 mL min/1.73 m2). 
Kieneker et al. [14] studied the association between uri-
nary K+ excretion (using two 24-h urine samples) 
and CKD in the PREVEND cohort (general population 
enriched for subjects with albuminuria). CKD was de-
fined as de novo development of an eGFR < 60 mL/
min/1.73 m2 and/or albuminuria > 30 mg/day. Each stan-
dard deviation decrement in urinary K+ excretion 
(21 mmol/day) was independently associated with a 16% 
higher risk of developing CKD. We performed a similar 
analysis in adult outpatients with long-term follow-up 
(median 12.7 years), which again showed that higher K+ 
intake (> 80 mmol/day) was associated with a lower risk 
of a 60% eGFR decline and RRT [17]. The study by He 
et al. [12] was conducted in the CRIC-cohort and ana-
lyzed the association between three 24-h urinary K+ ex-
cretions, halving of eGFR, and incident end-stage re-
nal  disease. In contrast with the other studies, this 
study found a higher risk of eGFR-decline and end-stage 
renal disease in the highest quartile of urinary K+ excre-
tion. Finally, Leonberg-Yoo et al. [15] studied the asso-
ciation between time-updated average urinary K+ excre-
tion, kidney failure, and all-cause mortality in a post hoc 
analysis of the Modification of Diet in Renal Disease 
Study. Higher urinary K+ excretion was not associated 
with kidney failure; however, each standard deviation in-
crease in urinary K+ (23 mmol/day) was associated with 
a 17% lower all-cause mortality rate in fully adjusted 
models.
The effect of K+ supplementation may be modulated 
by the accompanying anion. The anions chloride, 
 bicarbonate, and citrate have different metabolic path-
ways and are handled by different kidney transport 
mechanisms. Furthermore, alkali therapy may help to 
correct chronic metabolic acidosis of CKD. In fact, so-
dium bicarbonate supplementation was shown to slow 
the progression of CKD [40]. Recent data indicate that 
low ammonium excretion (which will also be mea-
sured in our trial) is associated with death and kidney 
failure in patients with CKD and hypertension, even 
among those without acidosis [46]. This raises the 
question whether potassium bicarbonate or potassium 
citrate may have an additive effect on slowing CKD 
progression. Although both bicarbonate and citrate 
correct chronic metabolic acidosis of CKD, hypoci-
traturia in CKD is common and may occur indepen-
dently of acidosis [47]. This provides the rationale to 
include both a potassium chloride and potassium ci-
trate intervention in our clinical trial.
Our study has a number of limitations. First, all par-
ticipants are requested to consume 6 (3 × 2) capsules/
day for 2 years on top of their prescribed medication, 
which will increase pill burden. Although higher K+ in-
take could also be achieved by changes in diet [48], this 
would not address the specific effect of K+. During the 
design of the trial we also performed a survey among the 
patient panel of the Dutch Kidney Patient Society which 
indicated they would prefer a capsule or tablet rather 
than a liquid formulation. In addition, because K+ has a 
specific taste, it would be difficult to design a placebo for 
the liquid formulation. The reason to select capsules in-
stead of tablets is that they are easier to swallow and 
easier to produce for the desired dosage. Second, there 
could be a trial effect in the sense that all participants 
may increase dietary K+ intake. This could attenuate the 
negative effects of a low K+ diet in the placebo group and 
therefore suppress the overall effect of K+ supplementa-
tion. However, because our supplementation will in-
crease dietary K+ intake to the recommended minimal 
intake, we think this diluting effect will be limited. Fi-
nally, we decided to estimate rather than to measure 
GFR because measuring GFR in such a large sample size 
would be logistically challenging. In addition, measured 
GFR may have more variation than eGFR, introducing 
Gritter/Vogt/Yeung/Wouda/Ramakers/
de Borst/Rotmans/Hoorn
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a larger error when using differences between 2 time-
points [49]. 
In conclusion, to our knowledge, the K+ in CKD study 
is the first clinical trial that will investigate the efficacy of 
K+ supplementation on attenuation of kidney function 
decline in CKD.
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